Lasokun (Ranolazine)

Ranolazine inhibits the late inward sodium current in cardiac cells, which lowers intracellular sodium and secondary calcium overload. This improves relaxation of heart muscle, enhances coronary perfusion, and relieves angina without significantly changing heart rate or blood pressure.

The appropriate dose of Lasokun is determined by the prescribing clinician based on the individual’s medical condition, renal function, and response to therapy. Dosage adjustments are made according to professional guidelines and patient monitoring.

Safety data for ranolazine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Lasokun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike beta‑blockers or calcium‑channel blockers, ranolazine does not significantly affect heart rate or blood pressure. It is often added when symptoms persist despite standard therapy, offering a different mechanism—late sodium current inhibition—that can improve angina control without additional hemodynamic effects.

Store Lasokun at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lasokun is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most critical safety concerns include QT interval prolongation, which can lead to serious ventricular arrhythmias, and rare cases of severe hepatic dysfunction or hypersensitivity reactions such as angioedema. Patients should be monitored for cardiac rhythm changes and liver function abnormalities.

Lasokun is contraindicated in patients with known hypersensitivity to ranolazine, severe hepatic impairment, or those taking strong CYP3A inhibitors that cannot be discontinued. Caution is also advised for individuals with pre‑existing QT prolongation or electrolyte disturbances.